Literature DB >> 15547529

Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer.

Philip E Castle1, Mark Schiffman, Cosette M Wheeler.   

Abstract

OBJECTIVE: The purpose of this study was to determine the clinical value of a semiquantitative measure of human papillomavirus viral load by the hybrid capture 2 assay for stratification of the risk of histologic cervical intraepithelial neoplasia grade 3 or carcinoma. STUDY
DESIGN: The Atypical Cells of Unknown Significance and Low-Grade Squamous Intraepithelial Lesions Triage Study was a randomized clinical trial of 5060 women with 2 years of follow-up to evaluate treatment strategies for women with equivocal or mildly abnormal cervical cytologic condition. The usefulness of the continuous hybrid capture 2 output relative light units/positive controls that were above the positive threshold (1.0 relative light units/positive controls), which was a surrogate for human papillomavirus viral load, for distinguishing between hybrid capture 2 positive women who were diagnosed with cervical intraepithelial neoplasia grade 3 or carcinoma during the study from those who were not diagnosed with cervical intraepithelial neoplasia grade 3 or carcinoma was examined with the use of receiver-operator characteristic analyses.
RESULTS: Relative light units/positive controls values did not further discriminate between hybrid capture 2 positive women with cervical intraepithelial neoplasia grade 3 or carcinoma from those with less than cervical intraepithelial neoplasia grade 3 or carcinoma. The use of a cervical intraepithelial neoplasia grade 2 or more severe or carcinoma case definition did not alter our findings.
CONCLUSION: Among women with atypical cells of unknown significance or low-grade squamous intraepithelial lesion cervical cytologic findings, the hybrid capture 2 viral load measurement did not improve the detection of 2-year cumulative cases of cervical intraepithelial neoplasia grade 3 or carcinoma significantly.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15547529     DOI: 10.1016/j.ajog.2004.05.018

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program.

Authors:  A T Hesselink; N W J Bulkmans; J Berkhof; A T Lorincz; C J L M Meijer; P J F Snijders
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

2.  Anal warts and anal intradermal neoplasia.

Authors:  Ignacio Echenique; Benjamin R Phillips
Journal:  Clin Colon Rectal Surg       Date:  2011-03

3.  Clinical Performance of APTIMA Human Papillomavirus (HPV) 16 18/45 mRNA Genotyping Testing for the Detection of Cervical Intraepithelial Neoplasia 3 (CIN3) or Cancer in a Select Group of Chinese Women.

Authors:  Yan-Li Guo; Ke You; Li Geng; Jie Qiao
Journal:  Pathol Oncol Res       Date:  2015-12-28       Impact factor: 3.201

4.  Effect of cervical cytologic status on the association between human papillomavirus type 16 DNA load and the risk of cervical intraepithelial neoplasia grade 3.

Authors:  Long Fu Xi; Nancy B Kiviat; Denise A Galloway; Xiao-Hua Zhou; Jesse Ho; Laura A Koutsky
Journal:  J Infect Dis       Date:  2008-08-01       Impact factor: 5.226

5.  High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease.

Authors:  Patti E Gravitt; Melinda Butsch Kovacic; Rolando Herrero; Mark Schiffman; Concepcion Bratti; Allan Hildesheim; Jorge Morales; Mario Alfaro; Mark E Sherman; Sholom Wacholder; Ana-Cecilia Rodriguez; Robert D Burk
Journal:  Int J Cancer       Date:  2007-12-15       Impact factor: 7.396

6.  Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women.

Authors:  N Muñoz; G Hernandez-Suarez; F Méndez; M Molano; H Posso; V Moreno; R Murillo; M Ronderos; C Meijer; A Muñoz
Journal:  Br J Cancer       Date:  2009-03-17       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.